Botulinum toxin A in treatment of cerebral palsy spasticity;Traitement de l'enfant infirme moteur cérébral par la toxine botulique A: Mode d'action, place des injections dans la prise en charge

Archives de Pediatrie

Volumn 9, Issue 9, 2002, Pages 928-933

  Carrelet, P ^a   Bollini, G ^a   Mancini, J ^a   Chabrol, B ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Botulinum Toxin; Cerebral Palsy

Indexed keywords

BOTULINUM TOXIN A;

ARM MUSCLE; CEREBRAL PALSY; CHILD; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; REVIEW; SOLEUS MUSCLE; SPASTICITY;

ACTIVITIES OF DAILY LIVING; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; GAIT; HUMANS; INJECTIONS, INTRAMUSCULAR; MUSCLE CONTRACTION; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 17344386705     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(02)00039-8     Document Type: Article

References (46)

1. Koman LM, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M. et al. Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108:1062-71.
2. Massin M, Allington F, Allington N. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 1999;19:362-5.
3. Koman LA, Mooney F, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomised, double blind, placebo-controlled trial. Botox study group. J Pediatr Orthop 2000; 20:108-15.
4. Boyd R, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebal palsy. Eur J Neurol 1999;6(Suppl 4):23-35.
5. Metaxiotis D, Siebel A, Doderlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop 2002;394:177-85.
6. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systemic review. Eur J Neurol 2001;8(suppl 5):1-20.
7. Koman A, Mooney J, Smith B, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary randomised, double blind trial. J Pediatr Orthop 1994;14:299-303.
8. Sutherland D, Kaufman K, Wyatt M, Chambers H, Mubarak S. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999;10:1-9.
9. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: a randomised controlled trial. Eur J Neurol 2001;8(Suppl 5):50-8.
10. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbah G, Muller J, et al. Botulinum toxin in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomised, double blind study of high dose versus low dose treatment. Neuropediatrics 1999;30:120-4.
11. Ubhi T, Bhakta B, Ives HL, Allgar V, Roussouni SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-7.
12. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtalmol Soc 1981;9:734-70.
13. Scott AV. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophtalmology 1980;87:1044-9.
14. Bouet H. La toxine botulique: du pouvoir toxique à l'utilisation thérapeutique. Thèse, Université Montpellier I Faculté de Pharmacie, 1999.
15. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-96.
16. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 1994;10:284-8.
17. Sheean GL. The management of spasticity with botulinum toxin. Eur J Neurol 1997;4(Suppl 2):41-5.
18. Pierrot-Deseilligny E, Pradat-Diehl P, Robain G. Physiopathologie de la spasticité. Ann Réadaptation Med Phys 1993:36:309-20.
19. Pierrot-Deseilligny E. Physiopathologie de la spasticité, Nieoullon, Poulain, Rascol, Christen, Les Amis du Clastridium Tome III. Solal 2000:31-8.
20. Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2000;42: 32-41.
21. Linder M, Schindler G, Michaelis U, Stein S, Kirschner J, Mall V, et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1 year follow-up using Gross Motor Function Measure. Eur J Neurol 2001;8(Suppl 5):120-6.
22. Mall V, Heinen F, Kirschner J, Linder M, Stein S, Michaelis U, et al. Evaluation of botulinum toxin A therapy in children with adductor spasm by Gross Motor Function Measure. J Child Neurol 2000:15: 214-7.
23. Galli M, Crivellini F, Santambrogio G, Fazzi F, Motta F. Short-term effects of botulinum toxin A as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. Funct Neurol 2001;16:317-23.
24. Corry S, Cosgrove AP, Duffy CM, Taylor TC, Graham HK. Botulinum toxin A in hamstring spasticity. Gait Posture 1999;10: 206-10.
25. Gormley ME, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol 2001;8(Suppl 5):127-35.
26. Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol 2001;16: 37-46.
27. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommandations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79.
28. Odergren T, Hjaltason H, Kaakola S, Solder SG, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psych 1998;64: 6-12.
29. Bakheit AM, Severa S, Cosgrove A, Morton R, Roussounis SH, Doderlein L, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001;43:234-8.
30. Gagnaire P, Burbeau P, Daussange J, Mongour P, Mensire A, Lagueny A. Utilisation de la toxine botulique dans le traitement du pied spastique chez l'enfant IMC. Motricité Cérébrale 1997;18: 125-31.
31. Suputtitada A. Managing spasticity in pediatric palsy using a very low dose of botulinum toxin type A: preliminary report. Am J Phys Med Rehabilitation Medicine 2000;79:320-6.
32. Corry IS, Cosgrove AP, Walsh EG, Mc Clean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39:185-93.
33. Autti-Ramo I, Larsen A, Peltonen J, Taimo A, Von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000;31:4-8.
34. Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol 2001; 8(Suppl. 5):145-9.
35. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-7.
36. Hurwitz EA, Conti GE, Flansburg EL, Brown SH. Motor control testing of upper limb function after botulinum toxin injection: a case study. Arch Phys Med Rehabil 2000;81:1408-15.
37. O'Brien C. Injection techniques for botulinum toxin using electro-myography and electric stimulation. Eur J Neurol 1997;4(Suppl. 2):47-51.
38. Willenborg MJ, Schilt JS, Smith BP, Estrada RL, Castle JA, Koman LA. Technique for ilio-psoas ultrasound-guided active electromyography-directed botulinum toxin A injection in cerebral palsy. J Pediatr Orthop 2002;22:165-8.
39. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast streching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999;35:71-7.
40. Corry IS, Cosgrove AP, Duffy CM, Mc Neil S, Taylor TC, Graham HK. Botulinum toxin A compared with streching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18:304-11.
41. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, et al. A randomised study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001;8(Suppl. 5):75-87.
42. Houltram J, Noble I, Boyd RN, Flett P, Graham HK. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence economic evaluation. Eur J Neurol 2001;8(Suppl. 5):194-202.
43. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997;4(Suppl. 2):15-22.
44. Molenaers G, Desloovere K, De Cat J, Jonkers I, De Borre L, Pauwels P, et al. Single event multilevel botulinum toxin A treatment and surgery: similarities and differences. Eur J Neurol 2001;8(Suppl. 5):88-97.
45. Leroy-Malherbe V, Laurent-Vannier A, Brugel DG, Urtizberea JA. Quoi de neuf en rééducation neurologique infantile? Arch Pediatr 2002;9:70-7.
46. Barwood S, Baillieu C, Boyd R, Bereton K, Nattrass G, Graham HK. Analgesic effects of botulinum toxin A: a randomised, placebo-controlled clinical trial. Dev Med Child Neurol 2000;42: 116-21.